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RESEARCH
Effectiveness of single dose rifampicin in preventing leprosy
in close contacts of patients with newly diagnosed leprosy:
cluster randomised controlled trial
F Johannes Moet, research fellow,1 David Pahan, medical doctor,2 Linda Oskam, senior researcher,3 Jan H
Richardus, associate professor,1 for the COLEP Study Group
ABSTRACT
Objective To determine the effectiveness of
chemoprophylaxis using a single dose of rifampicin to
prevent leprosy in close contacts.
Design Single centre, double blind, cluster randomised,
placebo controlled trial.
SettingLeprosy control programme in two districts of
northwestBangladeshwithapopulationofmore than four
million.
Participants28092 close contacts of 1037 patients with
newly diagnosed leprosy. 21711 contacts fulfilled the
study requirements.
Interventions A single dose of rifampicin or placebo given
to close contacts in the secondmonthof starting the index
patient’s treatment, with follow-up for four years.
Main outcome measure Development of clinical leprosy.
Results 18869 of the 21711 contacts (86.9%) were
followed-up at four years. Ninety one of 9452 contacts in
the placebo group and 59 of 9417 in the rifampicin group
had developed leprosy. The overall reduction in incidence
of leprosy using a single dose of rifampicin in the first two
years was 57% (95% confidence interval 33% to 72%).
The groups did not differ between two and four years. The
overall number needed to treat (NNT) to prevent a single
case of leprosy among contactswas 297 (95%confidence
interval 176 to 537). Differences were found between
subgroupsat twoyears,both in reductionof incidenceand
in NNT.
ConclusionA single dose of rifampicin given to contacts of
patients with newly diagnosed leprosy is effective at
preventing the development of clinical leprosy at two
years. The effect was maintained, but no difference was
seen between the placebo and rifampicin groups beyond
two years.
Trial registration Current Controlled Trials
ISRCTN61223447.
INTRODUCTION
For more than 60 years it has been known that close
contacts of patients with leprosy have an increased risk
of contracting the disease.1 The risk of a contact
developing clinical leprosy is related to the physical
and genetic distance to the index patient, the age of the
contact, and the classification of the index patient’s
disease.2
Since the early 1940s dapsone was the treatment of
choice for leprosy but was replaced in the early ’80s by
multidrug therapy—a combination of dapsone, clofa-
zimine, and rifampicin. Before multidrug therapy
became the standard treatment for leprosy, rando-
mised controlled trials using dapsone or acedapsone
investigatedwhether thesedrugs couldprevent leprosy
among contacts.3 4 A meta-analysis of the studies on
chemoprophylaxis with prolonged administration of
these drugs estimated anoverall efficacyof about 60%.5
The efficacy in household contacts ranged from 34-
54%,36 whereas in the community intervention trial it
was 91%.7 The disadvantages of dapsone as a
chemoprophylactic agent are the development of
drug resistance and the lack of patient compliance
because of the need for administration over a long
period. Therefore newer drugs were considered and
rifampicin was a logical choice because of its strong
bactericidal effect against Mycobacterium leprae, the
micro-organism causing leprosy. This drug was
expected to have at least a similar prophylactic effect
to dapsonebutwith fewer doses and shorterdurationof
administration. A protective efficacy of 40-50% with
rifampicin was reported in an uncontrolled trial.8 9
Recently an unblinded study on five Indonesian
islands used two doses of rifampicin, given with an
interval of about 3.5months.10 Three populationswere
compared: a “blanket group” consisting of the popula-
tion of three small islands on which prophylaxis was
given to all eligiblepeople, a “contact group” consisting
of the population of one island on which prophylaxis
was given only to contacts living in the samehousehold
or less than 50 m away, and a “control group”
consisting of the population of another island on
which no prophylaxis was given. In the blanket group,
chemoprophylaxis was associated with a 74.6% reduc-
tion in incidence of leprosy, at least during the three
years after implementation. In the population where
only household members and neighbours received
prophylaxis no reduction was observed.
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A large scale, double blind, placebo controlled trial
—the prospective (sero-) epidemiological study on
contact transmission and chemoprophylaxis in leprosy
(COLEP)—was started in northwest Bangladesh in
2002, using a single dose of rifampicin as chemopro-
phylaxis. Themethodologyof this trial and the analysis
of the intake data have been reported.2 11 We present
the results of the analysis after two and four years of
follow-up.
METHODS
The COLEP study was carried out in the districts of
Rangpur and Nilphamari, northwest Bangladesh, with
a population of more than four million people. We
excluded two subdistricts where the leprosy control
services were provided by organisations other than the
Danish Bangladesh Leprosy Mission. Eligible partici-
pants (patients and contacts) were informed verbally
about the study and invited to participate. Written
consent was obtained from all participants at recruit-
ment or from the parent or guardian of under 18s. The
study population consisted of close contacts of 1037
patients with newly diagnosed leprosy who were
willing to participate. Leprosy was diagnosed when at
least one of the cardinal signs was present—one or
more skin lesions consistent with leprosy and with
definite sensory loss, thickened peripheral nerves, and
a positive skin smear result for acid-fast bacilli.
We grouped patients with negative smear results at
all sites and who had no more than five skin lesions as
having paucibacillary leprosy, and those showing
positive smear results at any site or who had more
than five skin lesions as having multibacillary leprosy.
Within the paucibacillary group we classified those
with only one lesion as having single lesion pauciba-
cillary disease. As single lesion disease is the most
common form of leprosy in this area and because we
preferred to include a sufficient number of patients in
all categories, we limited the number of patients with
single lesion disease to 400. Of these we later
reclassified 11 on the basis of the skin smear results at
intake or the initially recorded clinical symptoms,
totalling 389 patients with single lesion paucibacillary
disease. Three hundred and fifty three patients had
paucibacillary leprosy with two to five lesions and 295
had multibacillary leprosy.
The intake of contacts started in June 2002 and was
completed by the end of December 2003. We
categorised contacts according to their physical and
genetic distance to the index patient. For physical
distance we defined six categories on the basis of the
local housing situation: shares a house and kitchen,
shares a kitchen only, shares a house but not kitchen,
next door neighbours, neighbours of the neighbours,
and social contacts (business contacts and colleagues
staying in the same room for at least four hours a day,
five days a week).
During the intake phase it seemed that only a small
proportionof the social contacts satisfied the criteria for
physical distance, and most were in fact neighbours of
the contacts who were classed as neighbours of the
neighbours. We therefore pooled these two groups in
the analysis. As only a small proportion of contacts
were sharing a house but not a kitchenwe pooled these
with contacts who were next door neighbours.
For genetic distance we initially defined seven
categories,2 11 but for analysis we combined these
categories to form two groups—closely related (parent,
child, or sibling) and not closely related (all others).
We excluded contacts when they refused informed
consent, were pregnant, were receiving treatment for
tuberculosis or leprosy during intake, had leprosy
(previously undiagnosed) at intake, were younger than
5 years, were known to have liver disease or jaundice,
or were residing only temporarily in the area. Contacts
could only be included in the contact group of one
patient.
We took finger prickblood samples from index cases
during intake and from contacts during intake and
follow-up to test for antibodies to M leprae specific
phenolic glycolipid-I. Samples were collected on
Schleicher and Schuell blotting paper GB 002, dried,
and stored at −20°Cuntil transport to theNetherlands.
An enzyme linked immunosorbent assay (ELISA) for
thedetectionof IgMantibodies tophenolic glycolipid-I
was done according to established procedures.12 The
antigen usedwas natural trisaccharide linked to bovine
serum albumin via a phenolic ring, a semisynthetic
analogue containing the M leprae specific terminal
trisaccharide moiety of phenolic glycolipid-I.
Index patients (n=1037) and contacts (n=28 092)
Randomisation on group level
Enrolment
Included contacts (n=21 711)
Allocation Allocated to and received
rifampicin prophylaxis
(n=10 857);
contact groups (n=517)
Allocated to and
received placebo
(n=10 854);
contact groups (n=520)
Excluded contacts (n=6381):
  Refused to participate (n=336)
  Absent (n=2217)
  Confirmed leprosy (n=159)
  Suspected leprosy (n=16)
  Other exclusion criterion present (n=3636)
  Not recorded (n=17)
Follow-up
2 years
Lost to follow-up
(n=906)
Lost to follow-up
(n=848)
Follow-up
4 years
Lost to follow-up
(n=1440)
Lost to follow-up
(n=1402)
Analysis Analysed (n=9417)Analysed (n=9452)
Flow of participants through trial
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Objective
We hypothesised that, firstly, transmission of M leprae
from the index patient to contacts would take place
before the diagnosis and start of treatment in the index
case, and, secondly, that a single dose of rifampicin
would be effective in eradicating small numbers of M
leprae that were possibly present in the contacts. In this
way rifampicin could be effective as a measure to
prevent clinical leprosy among close contacts of
patients with leprosy. Our objective was to determine
the effectiveness of chemoprophylaxis using a single
dose of rifampicin to prevent leprosy in close contacts.
We formed subgroups of contacts according to their
contact status, age, genetic relation to the indexpatient,
sex, disease classification of the index patient, presence
of a BCG scar, and serological status.
Outcome
The primary outcome was the development of clinical
leprosy.A leprosy control officer and amedical officer,
who also made a digital photograph of the lesions for
future reference, confirmed the disease of every patient
with newly found leprosy. The health professionals
confirming the diagnosis had aminimum of five years’
experience in the diagnosis of leprosy at referral centre
level.
Intervention
At intake—that is, after the index patient had received
the second supervised dose of multidrug therapy—all
contacts of one patient received treatment from the
same numbered container, which included either
capsules with 150 mg rifampicin or identical placebo
capsules without an active (antibiotic) ingredient. The
number on the container was the same as the central
registration number of the index case. According to
bodyweight and age, each contact took two to four
capsules under direct supervision of a staff member.
The dosage schedules were 600mg for adults weighing
35 kg and over, 450mg for adults weighing less than 35
kg and for children older than 9 years, and 300 mg for
children aged 5 to 9 years.
Randomisation
Randomisation of the rifampicin or placebo containers
was done by computerised methods by the database
designer (RF) in Rotterdam, the Netherlands. In this
way the randomisation was at contact group (cluster)
level. The codes were kept locked away in Rotterdam
and could only be accessed by the database designer.
The number on the container was identical to the
registration number of the index patient, and the
numbering followed the order of inclusion.
Follow-up
Two follow-up investigations took place. The first
started two years after intake, in June 2004, and was
completed in February 2006; the second started four
years after intake, in June 2006, and was completed at
the end of October 2007. The follow-ups followed the
sequenceof recruitment toachieveauniformfollow-up
period of 48 months. During the visits we examined as
many contacts as possible and if we could not see them
all wemade an appointment for a second visit to assess
the missed contacts. If we could still not get in touch
with the contacts we asked relatives to notify them
about coming to the clinic for examination. If contacts
had moved within reasonable distance, the field staff
tried to trace them at their new address.
If leprosy was diagnosed we recorded the date of
official registration. So as not to miss any new cases
emerging from the contact groupswe scanned themain
central registry and listed per clinic all patients found
during the two years between intake and follow-up
visits.We sent these lists to the clinics and asked if they
could check if any of the patients was a study contact.
Blinding
As only the database designer in Rotterdamhad access
to the treatment codes, the participants, the field and
hospital staff, and the primary researchers were
blinded. The total follow-up period of the trial was
48 months. To avoid compromising the double blind
Table 1 | Characteristics of contacts of patientswith newly diagnosed leprosy (n=18 869, 87%of
those included) after four years’ follow-up, by treatment allocation. Values are numbers
(percentages of total numbers) of contacts
Variable
Placebo group
(n=9452)
Rifampicin group
(n=9417)
Age at intake (years):
5-9 1497 (7.9) 1555 (8.2)
10-14 1500 (7.9) 1488 (7.9)
15-19 992 (5.3) 935 (5.0)
20-29 1667 (8.8) 1587 (8.4)
≥30 3795 (20.2) 3852 (20.5)
Genetic distance to index patient:
Closely related* 1475 (7.8) 1423 (7.5)
Not closely related† 7977 (42.3) 7994 (42.4)
Male 4343 (23.0) 4354 (23.1)
Female 5109 (27.1) 5063 (26.8)
Type of disease in index patient:
Multibacillary 2758 (14.6) 2486 (13.2)
Paucibacillary with 2-5 lesions 2954 (15.7) 3254 (17.2)
Single lesion paucibacillary 3740 (19.8) 3677 (19.5)
BCG scar absent 5552 (29.7) 5576 (29.8)
BCG scar present 3831 (20.5) 3760 (20.1)
Physical distance:
Shares kitchen and house 863 (4.6) 880 (4.7)
Shares kitchen only 687 (3.6) 684 (3.6)
Shares house only plus is next door neighbour 2645 (14.0) 2425 (12.9)
Neighbour of neighbour plus social contact‡ 5257 (27.9) 5428 (28.8)
ELISA result§:
Negative¶ 8106 (47.0) 8137 (47.2)
Positive** 515 (3.0) 494 (2.8)
ELISA=enzyme linked immunosorbent assay.
*Parent, child, or sibling.
†Other than parent, child, or sibling.
‡Business contacts and colleagues staying in same room at least four hours a day, five days a week.
§Contact population after two years’ follow-up.
¶Optical density <0.2.
**Optical density ≥0.2.
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design because of the mid-term analysis after
24 months’ follow-up, we gave the file with the data
of all contacts in the trial to the database designer. He
was asked tomerge this filewith his file of the treatment
codes. The combined file was given to the statistician
(GJJMB)whodid theanalyses.Hewasaskednot to give
the results of a particular analysis to the primary
researchers in case one of the numbers would be zero,
as this would compromise the blinding of the study.
After completion of the 48 months’ follow-up, the
codes were broken and the analysis of the trial carried
out unblinded.
Statistical analysis
We initially planned analyses at two and four years. If
there had been no effect at two years we could have
discontinued the trial. This was firstly because an effect
beginning after two years was unlikely and, secondly,
because an overwhelming effect would call for earlier
recommendations for implementation of the inter-
vention in routine leprosy control. This meant that, for
the sake of blinding, analyses such as a survival analysis
could not be done after the first follow-up period.
The power calculations were based on the total
follow-up period of four years. We did not make a
separate power calculation for the follow-up after two
years.When the proposal and protocol were prepared,
we stated that “appropriate analytical procedures”
would be used. The protocol version of September
2002 is the final version that the institutional review
board approved, and there were no protocol devia-
tions.
We determined that to detect reliably an expected
efficacy of intervention of 50%, even taking into
account an expected 10-20% loss to follow-up of
contacts, we needed 20 000 contacts, 10 000 in each
treatment arm. For the power calculation we assumed
an incidence rate of 2 per 1000 per year with an
expected 50% reduction through intervention, α=0.05
two sided, and 0.80 power. We enrolled 21 711
contacts in the trial, divided over 1037 clusters.
Statistical analyses were done using SAS software,
version 9.1. We used techniques for the analysis of
survey samples to account for the clustering at the level
of the index patient in the sample. Bivariate associa-
tionswere investigatedusing “proc surveyfreq” and the
Rao Scott χ2 instead of the Pearson χ2. Also we used
“proc surveylogistic” instead of the ordinary logistic
regression procedure. We report odds ratios, but
because of the low prevalence of the outcome these
are comparablewith relative risks.Thenumberneeded
to treat (NNT)was calculated per subgroupof contacts.
A significance level of 5% was used in all tests. We
converted the probabilities of having developed
leprosy during the follow-up period of two years to
incidence rates at one year assuming a constant hazard
during the period (rate=log (1-leprosy/total)/2). To
obtain confidence intervals we applied standard errors
for the probability (sqrt (1/leprosy+1/no leprosy)
around the log (rate).
RESULTS
The figure shows the numbers of participants in each
group. Overall, 28 092 eligible contacts were identi-
fied. Reasons for exclusion were absenteeism
(n=2217), refusal to participate (n=336), being a
temporary resident (n=131), age under 5 years
(n=2970), pregnancy (n=438), liver disease or jaundice
(n=51), current treatment for tuberculosis or leprosy
(n=42), contact of another patient in the trial (n=4),
suspected leprosy (n=16), confirmed leprosy (n=159),
and not recorded (n=17). This left 21 711 contacts
included in the trial.
The groups were well balanced for characteristics
(table 1). Of the 21 711 contacts included, 20 032
(92.3%)were seen during the first follow-up (over years
1 and 2) and 18 869 (86.9%) during the second follow-
up (over years 3 and 4). Among these, 96 new patients
with leprosy were found during the first follow-up and
Table 2 | Cases of leprosy in contacts of patientswith newly diagnosed leprosy by treatment during four years’ follow-up, with
incidence rates per 10<thin>000 person years at risk
Treatment
Leprosy
No leprosy
Total
investigated
Incidence rate per
10<thin> 000 person
years at risk (95% CI)
Single lesion
paucibacillary
Paucibacillary
with 2-5
lesions Multibacillary Total
Placebo
Follow-up (years):
1-2 28 30 9 67 9939 10 006 33.59 (26.42 to 42.72)
3-4 8 11 5 24 9361 9385 12.80 (8.58 to 19.11)
1-4 36 41 14 91 — —
Rifampicin
Follow-up (years):
1-2 15 10 4 29 9922 9951 14.59 (10.14 to 21.01)
3-4 16 8 6 30 9358 9388 16.00 (11.18 to 22.90)
1-4 31 18 10 59 — —
Overall reduction in incidence in rifampicin group:
During years 1-2, 56.5% (95% confidence interval 32.9% to 71.9%); Rao Scott χ2=13.476 (df=1), P=0.0002; overall number needed to treat 265 (95%
confidence interval 176 to 537).
During years 1-4, 34.9% (9.8% to 53.0%); Rao Scott χ2=5.4019 (df=1), P=0.02; overall number needed to treat 297 (170 to 1206).
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another 54 during the second follow-up, totalling 150
new patients with leprosy (table 2). During the first
follow-up leprosy had developed in 67 of 10 006
contacts in the placebo group (incidence rate 33.59 per
10 000 person years at risk) and 29 of 9951 contacts in
the rifampicin group (14.59 per 10 000 person years at
risk). During the second follow-up leprosy had devel-
oped in 24 of 9385 contacts in the placebo group (12.80
per 10 000 person years at risk) and 30 of 9388 in the
rifampicin group (16.00 per 10 000 person years at
risk).Over the four years of observation91participants
developed leprosy in the placebo group and 59 in the
rifampicin group. The reduction in incidence in the
rifampicin group was 56.5% (95% confidence interval
32.9% to 71.9%; P=0.0002) in the two years and 34.9%
(9.8% to 53.0%; P=0.02) during the four years. The
great reduction of new cases in the rifampicin group
occurred in the twoyears after treatment; in years 3 and
4 no statistically significant difference was found
between the number of new cases in the groups,
although the number was slightly higher in the
rifampicin group (30 v 24), which is predominantly
determined by more cases of single lesion paucibacil-
lary disease. The overall NNT to prevent one new case
of leprosywas265 (95%confidence interval 176 to537)
after two years and 297 (170 to 1206) after four years.
Table 3 shows theeffect of rifampicinprophylaxisby
variable category.This analysis is presented for the first
two years only because no statistically significant
(P<0.05) effect of the intervention was seen in the
third and fourth years, either overall or in the
individual variable categories (data not shown).
Rifampicin seems to be especially effective (odds
ratio <0.5, P<0.05) in contacts not closely related to
the index patient, in contacts of patients with pauciba-
cillary disease, in contacts with the largest physical
distance from the index patient, in females, in
seronegative contacts, in those without a BCG like
Table 3 | Effect of rifampicin prophylaxis in contacts of patientswith newly diagnosed leprosy by variable category at two years’
follow-up
Variable
Follow-up at two years
Placebo Rifampicin
Odds ratio (95% CI)* P value NNT†No leprosy Leprosy No leprosy Leprosy
Age (years):
5-9 1552 5 1608 4 0.77 (0.21 to 2.87) 0.6992 1370
10-14 1645 12 1616 2 0.17 (0.04 to 0.76) 0.0205 167
15-19 1107 7 1042 5 0.76 (0.24 to 2.39) 0.6372 663
20-29 1705 10 1688 1 0.10 (0.01 to 0.79) 0.0285 191
≥30 3962 33 4011 17 0.51 (0.28 to 0.91) 0.0237 248
Genetic distance to index
patient:
Closely related‡ 1585 18 1507 13 0.76 (0.35 to 1.65) 0.4862 374
Not closely related§ 8386 49 8458 16 0.32 (0.18 to 0.57) <0.0001 251
Male 4658 37 4660 17 0.46 (0.26 to 0.82) 0.0088 247
Female 5313 30 5305 12 0.40 (0.20 to 0.82) 0.0120 298
Type of disease in index
patient:
Multibacillary 2846 21 2626 10 0.52 (0.22 to 1.19) 0.1201 283
Paucibacillary with 2-5
lesions
3133 22 3408 9 0.38 (0.16 to 0.87) 0.0218 230
Single lesionpaucibacillary 3992 24 3931 10 0.42 (0.20 to 0.89) 0.0233 291
BCG scar absent 5878 52 5917 22 0.42 (0.26 to 0.69) 0.0007 197
BCG scar present 4023 15 3962 7 0.47 (0.18 to 1.26) 0.1342 513
Physical distance:
Shares house and kitchen 912 13 924 6 0.46 (0.15 to 1.38) 0.1652 132
Shares kitchen only 730 5 705 7 1.45 (0.38 to 5.52) 0.5863 NA
Shares house plus is next
door neighbour
2770 17 2544 8 0.51 (0.22 to 1.19) 0.1208 337
Neighbour of neighbour
plus social contact
5559 32 5792 8 0.24 (0.11 to 0.52) 0.0003 230
Negative ELISA result¶ 8054 52 8115 22 0.42 (0.25 to 0.70) 0.0009 269
Positive ELISA result** 511 4 492 2 0.52 (0.08 to 3.25) 0.4834 269
ELISA=enzyme linked immunosorbent assay.
*Odds ratio for leprosy in rifampicin group versus placebo group.
†Number needed to treat to prevent one case of leprosy.
‡Parent, child, or sibling.
§Other than parent, child, or sibling.
¶Optical density <0.2.
**Optical density ≥0.2.
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scar, and in the age groups 10-14 and 20-29. The odds
ratio and the NNT in the different age groups show a
trend that broadly mirrors the trend in incidence over
age in the placebo group—that is, the higher the
incidence, the less effective prophylaxis seems to be.
DISCUSSION
The overall incidence of leprosy among contacts of
patients with newly diagnosed disease can be reduced
by a single dose of rifampicin. A reduction of 57% was
achieved in the two years after treatment but no
statistically significant difference was observed
between the rifampicin and placebo groups in the
third and fourth years after treatment.
The prospective (sero-) epidemiological study on
contact transmission and chemoprophylaxis in leprosy
(COLEP) study was designed as a single centre,
prospective, cluster randomised,doubleblind, placebo
controlled trial to verify results of earlier studies that
did not have all of these methodological qualities. The
strength of the trial is its robust design and the large
number of participants who could be includedwithin a
fairly short time because of the relatively high
incidence of leprosy in the study area. We cannot be
certain that the results are equally applicable to
situations where leprosy is less highly endemic,
however, although we see no reason to assume
otherwise. It must also be kept in mind that this is an
analysis after four years of follow-up. A longer
observation time is necessary to show whether the
effect of rifampicin prophylaxis will be sustained over
longer periods.
The results of our study confirm those of previous
studies on the efficacy of rifampicin prophylaxis. It
seems, however, that this effect is not the same for all
subgroups of contacts. Contacts who were not closely
related to the index patient or lived further away, and
who on the basis of the intake data were expected to be
at a lower risk,2 benefitedmore fromprophylaxis. This
inverse relationbetweenefficacyandexpected riskalso
seems to exist for classification of disease in the index
patient. By contrast, a direct relation with age of the
contact is suggested, higher efficacy being recorded in
those groups with a higher incidence of leprosy.
Female contacts seemed to benefit slightly more
from prophylaxis than male contacts, but this was not
statistically significant as the confidence intervals
overlapped to a great extent. Although males are
generally regardedasbeingmore at risk for leprosy,13 14
neither our intake data nor the presently discussed
values could confirm a significantly higher risk. A
reason for the difference in efficacy between the sexes,
if present, could be that females, who are generally
lighter, had a relatively higher dose of rifampicin and
more often developed paucibacillary disease rather
than multibacillary disease. This assumption would
need further investigation.
Prophylaxis seemed somewhat more effective in
those contacts whowere seronegative for antibodies to
M leprae specific phenolic glycolipid-I at intake. Studies
on the prognostic value of serology have shown
contradictory findings,15-17 but research has indicated
that contacts who are seropositive for antibodies to M
leprae specific phenolic glycolipid-I are at an increased
risk of developing leprosy, especially multibacillary
disease.18
The incidence rate of new cases of leprosy in the
placebo groupbetween two and four years of follow-up
showed a downward trend, whereas the rate remained
similar in the rifampicin group over the two observa-
tion periods (see table 2). The downward trend in the
placebo group can be understood from the perspective
that regular surveys of contactswith treatment of newly
detected cases is in itself an intervention by removing
potential sources of infection and thereby reducing
transmission to the contacts, which in turn can be
expected to lead to a decreasing incidence rate in the
contact groups over time. The difference between the
placebo and rifampicin groups is determinedprimarily
by a reduction of paucibacillary (single lesions and 2-5
lesions) leprosy in the rifampicin group in the first two
years. After four years’ follow-up we cannot yet
establish to what extent there is a true prevention of
new cases of leprosy by intervention with rifampicin.
There may be merely a delay in the occurrence of
disease, which can only be confirmed through a longer
observation period.
Finally, the presence of a BCG scar did not affect the
response to prophylaxis, as measured by odds ratios.
As BCG has a complementary effect to rifampicin in
preventing leprosy, the absolute numbers of new
patientswith leprosyamong thosevaccinated is smaller
and therefore the NNT is higher.
The findings of our trial are consistent with those of a
study from Indonesia.10 That study found no effect of
rifampicin in communities where only household
contacts and direct neighbours were given prophy-
laxis, but showeda significant effect in those commu-
nities where everybody was given prophylaxis. But
even in those communities, rifampicin prophylaxis
seemed to be more effective in non-contacts than in
household contacts. Studies on dapsone prophylaxis
also showed that this was more effective when given as
a blanket treatment rather than only to household
contacts.5 A possible explanation of these findings
could be that by the time the prophylaxis is given the
potential bacillary load in physically close contacts,
closely related contacts, seropositive contacts, and
contacts of patients with multibacillary disease is on
averagealready toohigh tobeeliminatedbya single (or
double, in Indonesia two doses were given) dose of
rifampicin. This possibly higher average bacterial load
could be caused either by a higher exposure (house-
hold contacts, contacts of patients with multibacillary
disease) or by a higher vulnerability (genetic make-up,
partly reflected in seropositivity, male sex). If a higher
bacterial load is indeed a reason for failure of
prophylaxis with a single dose of rifampicin, more
extended chemoprophylaxis schedulesmaybeneeded
in those groups of contacts, but this requires further
research.
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In summary, a single dose of rifampicin given to
contacts of new patients with leprosywas 57% effective
in preventing the development of clinical leprosy after
two years but a further effect could not be shown
between twoand fouryears.This efficacy at twoyears is
similar to that found in a meta-analysis of dapsone
trials, although in those trials dapsone was given for
1-5 years.5 The finding of single dose rifampicin as a
cheap and practical preventive intervention for con-
tacts of patients with leprosy in leprosy control
programmes is a promising. The effect is not consistent
in all subgroups, requiring further study before
recommendations can be made for routine implemen-
tation.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Chemoprophylaxis with prolonged administration of dapsone had an overall efficacy in
preventing leprosy in contacts of about 60%
Two doses of rifampicin had a protective efficacy of 40-50% in an uncontrolled trial
WHAT THIS STUDY ADDS
A single dose of rifampicin in contacts of new patients with leprosy was 57% effective at
preventing the development of leprosy after two years
No further effect was found between two and four years
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